Subverting Cancer’s Ability to Evade Therapy

Targeting Adapative Resistance

Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms.

Adaptive Resistance is Complex…

  • Cancer cells adapt to chemo- and targeted therapies by co-opting signaling pathways previously thought to only be utilized by the host immune system. This is referred to as adaptive resistance
  • This adaptive resistance mechanism allows the cancer cell to survive conventional chemotherapeutic and targeted therapies (e.g. FLT3 inhibitors) by activating IRAK1 and IRAK4 kinases

…But Kurome Has a New Approach

  • In pre-clinical trials, we have shown that inhibiting IRAK1 and IRAK4 provides an overall survival benefit in MDS and AML cells by suppressing this adaptive resistance mechanism in naïve and relapsed / refractory cancer
  • IRAK1 and IRAK4 are also co-opted in a variety of cancer cell backgrounds, where their inhibition suppresses the survival of the cancer cells

Our Technology

A targeted approach for treating hematological cancers and beyond

PDX Graph

Kurome Therapeutics is a preclinical stage company that is developing a series of IRAK1/4, panFLT3 inhibitors. Preclinical studies have demonstrated:

  • Broad range of efficacy in MDS and AML patient-derived cell lines
  • Synergy with Venclexta® (Venetoclax) to improve Venclexta® potency
  • Identification of a biomarker that correlates with prognosis in AML patients and maximal activation of immune signaling through this pathway in AML cells
  • Increased overall survival in cell line and patient-derived xenograft models, well beyond that of existing FLT3 inhibitors
  • Maintenance of complete efficacy even in settings of adaptive resistance to FLT3 inhibitors and in settings of FLT3 mutations

Kurome’s Team

A seasoned technical management team with more than 50 years of combined experience in Pharma and Biotech investment and program execution.

Management
Jan Rosenbaum

Jan Rosenbaum, PhD

President & CEO / Chief Scientific Officer
  • Engaged by CCHMC’s Innovation Ventures to establish value proposition and business case
  • Over 25 years Pharma, Biotech technical management experience
  • Former CSO, Airway Therapeutics; 5 years CincyTech; Advisory Panel, Harrington Discovery Institute
  • 12 patents and >35 publications
John Rice

John Rice, PhD

Executive Chairman
  • Managing Director, CincyTech
  • 30 years investing, 13 years R&D management experience
  • Currently Chairman, Airway Therapeutics, Eccrine Systems, Genetesis, Xact Medical
  • Member of the Board: Enable Injections, Meridian Biosciences
  • Founder & Former Chair, Akebia and Aerpio
Scientific Advisory Board
Daniel Starczynowski

Daniel Starczynowski, PhD

Chairman
  • Scientific Founder, Kurome Therapeutics
  • Professor, Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center (CCHMC)
  • Katherine Stewart Waters Endowed Chair of Hematologic Malignancies
  • Forty under 40 (Cincinnati Business Courier) and NHLBI Emerging Investigator Award recipient
  • 9 patents and >50 publications
Board of Directors
Abram Gordon

Abram Gordon, JD

Board Member
  • Interim Vice President, CCHMC’s Innovation Ventures
  • Executive Director, Cincinnati Children’s Proton Therapy Center
  • Attorney with 20+ years of legal and management experience in several different industries
Manish Bhandari

Manish Bhandari, MD

Board Member
  • Oncologist, educated Harvard Medical School & Univ of Michigan; with 15 year oncology practice experience
  • Investigator in over 24 oncology therapeutic/targeted therapy trials in malignant hematology and Oncology
  • Awarded "Unsung Hero" award by Cancer Family care and "Lifetime achievement award" as Oncology Luminary for cancer susceptibility testing
  • Over dozen publications in Oncology and malignant hematology
  • Angel investor in over half dozen biotech and medtech startups (Blinkpad, Zenspace, Enable injections, Blue Water Vaccines, SayanMil Scientific)
  • Oncology patient motivational speaker
Jan Rosenbaum

Jan Rosenbaum, PhD

President & CEO / Chief Scientific Officer
  • Engaged by CCHMC’s Innovation Ventures to establish value proposition and business case
  • Over 25 years Pharma, Biotech technical management experience
  • Former CSO, Airway Therapeutics; 5 years CincyTech; Advisory Panel, Harrington Discovery Institute
  • 12 patents and >35 publications
John Rice

John Rice, PhD

Executive Chairman
  • Managing Director, CincyTech
  • 30 years investing, 13 years R&D management experience
  • Currently Chairman, Airway Therapeutics, Eccrine Systems, Genetesis, Xact Medical
  • Member of the Board: Enable Injections, Meridian Biosciences
  • Founder & Former Chair, Akebia and Aerpio

News & Research

Filter:
NA P&G alum tapped as CEO of Cincinnati Children’s spin-out company
29 April 2020
Cincinnati Business Courier
RP Targeting AML-associated FLT3 mutations with a type I kinase inhibitor
Jones LM et al - 2020
Journal of Clinical Investigation
RP Overcoming adaptive therapy resistance in AML by targeting immune response pathways
Melgar K et al – 2019
Science Translational Medicine
RP IRAK signalling in cancer
Rhyasen GW and Starczynowski DT – 2015
British Journal of Cancer
RP IRAK1: Oncotarget in MDS and AML
Beverly LJ and Starczynowski DT - 2014
Oncotarget